A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines. We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries. Our products include: Therapeutic area Certain Indications Cardiometabolic Health products In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 65.2B | 65.2B | 45.0B | 34.1B | 28.5B | 28.3B |
| Net Income | 20.6B | 20.6B | 10.6B | 5.2B | 6.2B | 5.6B |
| EPS | $22.95 | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Free Cash Flow | 9.0B | 9.0B | 3.8B | 793M | 5.7B | 6.0B |
| ROIC | 33.7% | 41.6% | 24.2% | 14.1% | 25.0% | 25.1% |
| Gross Margin | 83.0% | 83.0% | 77.3% | 79.2% | 76.8% | 74.2% |
| Debt/Equity | 1.66 | 1.66 | 2.72 | 2.98 | 1.67 | 2.05 |
| Dividends/Share | $5.99 | $6.23 | $5.40 | $4.69 | $4.07 | $3.53 |
| Operating Income | 26.6B | 26.6B | 13.5B | 7.0B | 7.1B | 6.5B |
| Operating Margin | 40.9% | 40.9% | 29.9% | 20.6% | 25.0% | 22.9% |
| ROE | 77.8% | 101.2% | 74.2% | 48.6% | 58.6% | 62.2% |
| Shares Outstanding | 899M | 899M | 904M | 904M | 905M | 912M |
ELI LILLY & Co passes 7 of 9 quality checks, indicating strong fundamentals.
ELI LILLY & Co trades at 40.5x trailing earnings, compared to its 15-year median P/E of 43.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 97.7x vs a median of 28.1x. The company's 5-year average ROIC is 26.0% with a gross margin of 78.1%. Total shareholder yield (dividends + buybacks) is 1.1%. At current prices, the estimated annualized return to fair value is -11.5%.
ELI LILLY & Co (LLY) has a current P/E ratio of 40.5, compared to its historical median P/E of 43.4. The stock is currently considered Fair based on its historical valuation range.
ELI LILLY & Co (LLY) has a 5-year average return on invested capital (ROIC) of 26.0%. This indicates strong capital allocation and a potential competitive advantage.
ELI LILLY & Co (LLY) has a market capitalization of $836.0B. It is classified as a mega-cap stock.
Yes, ELI LILLY & Co (LLY) pays a dividend with a trailing twelve-month yield of 0.64%. The company also returns capital through share buybacks, with a buyback yield of 0.49%.
Based on historical P/E analysis, ELI LILLY & Co (LLY) appears fair. The current P/E of 40.5 is 7% below its historical median of 43.4. The estimated fair value CAGR (P/E method) is 15.1%.
ELI LILLY & Co (LLY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ELI LILLY & Co (LLY) reported annual revenue of $65.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
ELI LILLY & Co (LLY) has a net profit margin of 31.7%. This is a strong margin indicating high profitability.
ELI LILLY & Co (LLY) generated $9.0 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ELI LILLY & Co (LLY) has a debt-to-equity ratio of 1.66. This indicates higher leverage, which may increase financial risk.
ELI LILLY & Co (LLY) reported earnings per share (EPS) of $22.95 in its most recent fiscal year.
ELI LILLY & Co (LLY) has a return on equity (ROE) of 101.2%. This indicates the company generates strong returns for shareholders.
ELI LILLY & Co (LLY) has a 5-year average gross margin of 78.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for ELI LILLY & Co (LLY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ELI LILLY & Co (LLY) has a book value per share of $29.50, based on its most recent annual SEC filing.